BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1911 related articles for article (PubMed ID: 21741092)

  • 1. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
    Nelson H; Lehmann L; Blaiss MS
    Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
    J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
    Senna GE; Calderon M; Milani M
    Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
    Malling HJ; Lund L; Ipsen H; Poulsen L
    J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.
    Valovirta E; Berstad AK; de Blic J; Bufe A; Eng P; Halken S; Ojeda P; Roberts G; Tommerup L; Varga EM; Winnergard I;
    Clin Ther; 2011 Oct; 33(10):1537-46. PubMed ID: 21999887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets.
    Panizo C; Cimarra M; González-Mancebo E; Vega A; Senent C; Martín S
    J Investig Allergol Clin Immunol; 2010; 20(6):454-62. PubMed ID: 21243928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.
    Nolte H; Hébert J; Berman G; Gawchik S; White M; Kaur A; Liu N; Lumry W; Maloney J
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):450-456.e4. PubMed ID: 23706715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J; Ribel M; Herold DA
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
    Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
    Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
    Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.